Navigation Links
Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
Date:10/29/2008

biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com.

This press release contains "forward-looking" statements. These include statements concerning the potential for TELCYTA to treat ovarian cancer and the effectiveness of TELCYTA in combination with PLD and in patients under certain platinum refractory and platinum resistant conditions. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including the risks associated with clinical trials and the interpretation of resulting data. Detailed information regarding these and other factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended June 30, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc. '/>"/>

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
2. Telik Announces Receipt of Nasdaq Notice
3. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
4. ReceptorBio Announces Diabetes License Agreement With Telik
5. Telik Announces Financial Results For 2008 Second Quarter
6. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
7. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
8. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
9. Telik Announces First Quarter 2008 Financial Results
10. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
11. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Patheon Inc ., a leading provider of contract ... will host a complimentary webinar on “Cleaning Validation: Science, ... 4, 2013 at 11 a.m. Eastern Standard Time. ... regulations for cleaning validation. Many companies have incorporated ... evaluation of risk. Some companies have chosen to ...
(Date:5/23/2013)... -- Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., a ... and therapeutics, announced today that StemCyte has become an ... car driven by James Jakes . ... 2013 season.   StemCyte, Inc. and Rahal Letterman ... umbilical cord blood banking and its educational initiative ,Stars ...
(Date:5/23/2013)... MA (PRWEB) May 23, 2013 ... inch wide and provide 15 mm travel range ... The small dimensions make these new positioners ... confined spaces. A vacuum rated version is also ... Drawings, specifications and datasheets can be found at: ...
(Date:5/23/2013)...  Saddleback Memorial Medical Center in Laguna ... on the West Coast to perform a hysterectomy using ... women with a state-of-the-art, minimally invasive approach to gynecological ... , M.D., a highly regarded Orange County ... minimally invasive surgery at Saddleback Memorial, led the surgical ...
Breaking Biology Technology:Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3
... Up, Net Loss Down, Cash Position Strong, as Pipeline ... Continues to ... EXEL ) today reported financial results for the full,year and fourth quarter ... compared to $98.7 million in,2006. The increase in revenues for the full ...
... Feb. 14 SectorWatch.biz announces the,availability of MarketStats ... and,driving markets today., Investors can view all ... http://www.SectorWatch.biz -- Click on MarketStats, Today,s ... Therapeutics, Inc. (OTC Bulletin Board: CVBT), Boston,Scientific Corp. ...
... Company brings in experienced industry professionals to help grow U.S. ... ... Feb. 14 /PRNewswire/ - Touch,Bionics, developer of the i-LIMB Hand, the world,s ... production and design teams to bolster growing demand in the,United States., ...
Cached Biology Technology:Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA 2Touch Bionics adds to sales, marketing, production and design teams 2Touch Bionics adds to sales, marketing, production and design teams 3
(Date:5/23/2013)... Inside the natural history museums of the world are ... and beetles to flowers, mushrooms and grasses, all stacked, ... The rich and diverse collections could be critical to ... face of a growing human footprint if only ... project, brought to life with the help of a ...
(Date:5/23/2013)... pathogens are growing increasingly resistant to the conventional antibiotics ... scientists has synthesized a potent new class of compounds ... , Writing online in the Journal of the ... of Wisconsin-Madison chemistry Professor Helen Blackwell describes agents that ... Staphylococcus aureus , a bacterium at the root of ...
(Date:5/22/2013)... fuel cell powered buses, including a team from ... degradation processes and bus membrane durability. , The ... stressors in the operating cycle of the bus ... the study, led by SFU graduate student Natalia ... at Burnaby-based Ballard Power Systems and funded by ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4University of Wisconsin chemists find new compounds to curb staph infection 2Tests lead to doubling of fuel cell life 2
... is pleased to announce the recipients of its 2011 ... at the Society,s 55th Annual Meeting on Monday, March ... Maryland. The awardees are: Shelagh Ferguson-Miller, Michigan ... for her seminal contributions to the field of molecular ...
... one in every six Americans who have ever been ... according to Penn State College of Medicine researchers. ... trials report, the majority of Americans are still unable ... who lose weight and successfully maintain that loss may ...
... Spanish . , Afla-Guard, a biological control used ... used on corn as well, according to a study by ... After extensive study and research trials in Texas, ... for use on corn, beginning with the 2009 crop. ...
Cached Biology News:Biophysical Society names 2011 award recipients 2Americans struggle with long-term weight loss 2Americans struggle with long-term weight loss 3
...
... Blunt-Ended PCR Cloning Kit, 40 ... efficient cloning of all PCR products ... TA cloning approaches by offering consistently ... as 25-fold more positive clones.Amplicons generated ...
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
... Peptide sequences: Two separate vials ... to the same sequence used as ... (Catalog No. 160890) ... Cayman's guanylate cyclase polyclonal antiserum (Catalog ...
Biology Products: